We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
India’s Bharat Biotech has finalized enrollment for a phase 3 trial of its COVID-19 vaccine, Covaxin, which Indian regulators approved Jan. 3 for emergency use. Read More
A small randomized trial in Argentina has found that the early use of convalescent plasma in COVID-19-infected adults helped to reduce progression to severe disease. Read More
German vaccine developer CureVac has secured a deal with Bayer to help gain regulatory approvals worldwide for its messenger RNA-based COVID-19 vaccine candidate, CVnCoV. Read More
Scientists are closely monitoring the potential impact of mutations of the SARS-CoV-2 virus on the effectiveness of COVID-19 vaccines, but for the moment the new strains don’t appear able to completely evade their protective effect. Read More
Italy’s Angelini Pharma announced plans to purchase Swiss drugmaker Arvelle Therapeutics in a deal worth up to $960 million, gaining access to the epileptic seizure drug cenobamate which it plans to market in Europe. Read More
Amerisource Bergen, the second largest U.S. wholesale drug distributor, announced that it is acquiring the Walgreens Boots Alliance European distribution unit, Alliance Healthcare, in a deal valued at $6.5 billion. Read More
The long-time director of the FDA’s Center for Drug Evaluation and Research (CDER), Janet Woodcock, who stepped aside last year to head the therapeutics arm of the U.S. government’s Operation Warp Speed (OWS) initiative, is taking up a new role as principal medical adviser to FDA Commissioner Stephen Hahn. Read More
The European Commission granted conditional marketing authorization for Moderna’s highly effective COVID-19 vaccine Wednesday, adding a second messenger RNA-based vaccine to its arsenal against the pandemic. Read More